| scholarly article | Q13442814 |
| P356 | DOI | 10.3389/FONC.2017.00306 |
| P8608 | Fatcat ID | release_ml6x6jkuyfe4xervcxer7vcpwi |
| P932 | PMC publication ID | 5770653 |
| P698 | PubMed publication ID | 29376023 |
| P50 | author | Michele Galluccio | Q40639510 |
| Lara Console | Q57019304 | ||
| P2093 | author name string | Cesare Indiveri | |
| Lorena Pochini | |||
| Mariafrancesca Scalise | |||
| P2860 | cites work | Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma | Q87403819 |
| Transport mechanism and regulatory properties of the human amino acid transporter ASCT2 (SLC1A5) | Q87427376 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1 | Q24312292 | ||
| Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1 | Q24313010 | ||
| Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family | Q24316388 | ||
| Understanding the Warburg effect: the metabolic requirements of cell proliferation | Q24604760 | ||
| mTOR signaling in growth control and disease | Q24634174 | ||
| Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans | Q28251733 | ||
| Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19 | Q28275118 | ||
| Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening | Q28550085 | ||
| Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development | Q28831339 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Bidirectional transport of amino acids regulates mTOR and autophagy | Q29614476 | ||
| Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia | Q29616650 | ||
| c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism | Q29617213 | ||
| Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts | Q33415058 | ||
| Amino acid homeostasis and signalling in mammalian cells and organisms | Q33727454 | ||
| The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer | Q33793170 | ||
| From Krebs to clinic: glutamine metabolism to cancer therapy. | Q33834498 | ||
| Ferroptosis as a p53-mediated activity during tumour suppression | Q34043533 | ||
| Recent molecular advances in mammalian glutamine transport | Q34353945 | ||
| Cysteine is not a substrate but a specific modulator of human ASCT2 (SLC1A5) transporter | Q86540388 | ||
| Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity | Q34421311 | ||
| Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis? | Q34482056 | ||
| SLC6 transporters: structure, function, regulation, disease association and therapeutics | Q34649517 | ||
| Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance | Q34894810 | ||
| Pyruvate carboxylase is required for glutamine-independent growth of tumor cells | Q35008346 | ||
| Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth | Q35458543 | ||
| Defining substrate and blocker activity of alanine-serine-cysteine transporter 2 (ASCT2) Ligands with Novel Serine Analogs | Q35776745 | ||
| Molecular mechanisms of glutamine action | Q36082609 | ||
| Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? | Q36139606 | ||
| Targeting cancer metabolism at the plasma membrane by limiting amino acid access through SLC6A14. | Q36185250 | ||
| Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling | Q36228895 | ||
| Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer | Q36268839 | ||
| High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma | Q36310209 | ||
| Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. | Q36330223 | ||
| Reductive carboxylation supports redox homeostasis during anchorage-independent growth | Q36883158 | ||
| LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs | Q36923089 | ||
| ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. | Q37023688 | ||
| Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells. | Q37065899 | ||
| SLC7A5 Functions as a Downstream Target Modulated by CRKL in Metastasis Process of Gastric Cancer SGC-7901 Cells | Q37419580 | ||
| A novel glutaminase isoform in mammalian tissues. | Q37476077 | ||
| Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism | Q37594451 | ||
| Glutaminase regulation in cancer cells: a druggable chain of events. | Q37707215 | ||
| Plasma-free amino acid profiles are predictors of cancer and diabetes development | Q37737774 | ||
| A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells | Q38030239 | ||
| The SLC38 family of sodium-amino acid co-transporters. | Q38160180 | ||
| Membrane transporters for the special amino acid glutamine: structure/function relationships and relevance to human health. | Q38243334 | ||
| Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter | Q38356396 | ||
| Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs | Q38412222 | ||
| ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma | Q38651973 | ||
| Drug-induced amino acid deprivation as strategy for cancer therapy | Q38657061 | ||
| Glutamine transporters in mammalian cells and their functions in physiology and cancer | Q38685207 | ||
| The MYC mRNA 3'-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels. | Q38707758 | ||
| LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells | Q38749717 | ||
| LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma | Q38754089 | ||
| A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis | Q38767151 | ||
| Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting | Q38795490 | ||
| Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells | Q38810699 | ||
| LAT1 is the transport competent unit of the LAT1/CD98 heterodimeric amino acid transporter. | Q38845153 | ||
| Mitochondrial Chemical Biology: New Probes Elucidate the Secrets of the Powerhouse of the Cell | Q38914628 | ||
| Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma. | Q38930757 | ||
| Synthesis and preliminary biological evaluation of O-2((2-[(18)F]fluoroethyl)methylamino)ethyltyrosine ([(18)F]FEMAET) as a potential cationic amino acid PET tracer for tumor imaging. | Q38997841 | ||
| Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment | Q39112756 | ||
| Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder | Q39135788 | ||
| Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. | Q39225768 | ||
| Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. | Q39249420 | ||
| Mitochondrial dysfunction and potential anticancer therapy. | Q39418003 | ||
| Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. | Q39456571 | ||
| Glutamine transport. From energy supply to sensing and beyond | Q39941261 | ||
| A Critical Role of Glutamine and Asparagine γ-Nitrogen in Nucleotide Biosynthesis in Cancer Cells Hijacked by an Oncogenic Virus | Q40082053 | ||
| Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer | Q41126596 | ||
| LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation | Q41412927 | ||
| Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma | Q41519274 | ||
| Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer | Q41573099 | ||
| Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer | Q41588157 | ||
| Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma | Q41645489 | ||
| A metabolic core model elucidates how enhanced utilization of glucose and glutamine, with enhanced glutamine-dependent lactate production, promotes cancer cell growth: The WarburQ effect | Q42706654 | ||
| Proteoliposomes as tool for assaying membrane transporter functions and interactions with xenobiotics | Q42873690 | ||
| Identification and purification of the reconstitutively active glutamine carrier from rat kidney mitochondria | Q42991112 | ||
| Right on TARGET: glutamine metabolism in cancer | Q43242538 | ||
| Glutamine transport in submitochondrial particles | Q44843295 | ||
| Large scale production of the active human ASCT2 (SLC1A5) transporter in Pichia pastoris--functional and kinetic asymmetry revealed in proteoliposomes | Q45146953 | ||
| Up-regulation of the amino acid transporter ATB(0,+) (SLC6A14) in carcinoma of the cervix | Q46707863 | ||
| Transporters in drug development and clinical pharmacology | Q46880795 | ||
| Effects of targeting SLC1A5 on inhibiting gastric cancer growth and tumor development in vitro and in vivo | Q46913425 | ||
| Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer | Q47128109 | ||
| Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: Toward a novel active targeting strategy in breast cancer therapy | Q48922411 | ||
| Potent inhibitors of human LAT1 (SLC7A5) transporter based on dithiazole and dithiazine compounds for development of anticancer drugs. | Q50890077 | ||
| Glutaminolysis and carcinogenesis of oral squamous cell carcinoma. | Q51010116 | ||
| L-amino acid transporter 1 may be a prognostic marker for local progression of prostatic cancer under expectant management. | Q53560152 | ||
| Glutamine Transport in Normal and Acidotic Rat Kidney Mitochondria | Q60662709 | ||
| L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia | Q60877151 | ||
| Metabolism of [U-13C]glutamine and [U-13C]glutamate in isolated rat brain mitochondria suggests functional phosphate-activated glutaminase activity in matrix | Q80975523 | ||
| Expression of human heteromeric amino acid transporters in the yeast Pichia pastoris | Q85239521 | ||
| Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma | Q85257484 | ||
| P921 | main subject | cell growth | Q189159 |
| P304 | page(s) | 306 | |
| P577 | publication date | 2017-12-11 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Glutamine Transport and Mitochondrial Metabolism in Cancer Cell Growth | |
| P478 | volume | 7 |
| Q91632528 | A PET Glutamate Analogue to Measure Cancer Cell Redox State and Oxidative Stress: Promise and Paradox |
| Q92534707 | A review of the alleged health hazards of monosodium glutamate |
| Q100491018 | ATP modulates SLC7A5 (LAT1) synergistically with cholesterol |
| Q94562053 | Amino acid transporters: Emerging roles in drug delivery for tumor-targeting therapy |
| Q57787438 | Change in Amino Acid Pools During Neuronal Differentiation of PC12 Cells |
| Q92763948 | Deciphering the galectin-12 protein interactome reveals a major impact of galectin-12 on glutamine anaplerosis in colon cancer cells |
| Q55497799 | Editorial: Cell Stress, Metabolic Reprogramming, and Cancer. |
| Q90576157 | Emerging roles of Myc in stem cell biology and novel tumor therapies |
| Q92715598 | Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer |
| Q57174877 | Homology Modeling Informs Ligand Discovery for the Glutamine Transporter ASCT2 |
| Q92675121 | Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells |
| Q92990752 | Lobetyolin induces apoptosis of colon cancer cells by inhibiting glutamine metabolism |
| Q60907690 | Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States |
| Q98613151 | Mitochondrial uncoupling and the disruption of the metabolic network in hepatocellular carcinoma |
| Q99207644 | Stirred suspension bioreactors maintain naïve pluripotency of human pluripotent stem cells |
| Q58764807 | The Human SLC1A5 (ASCT2) Amino Acid Transporter: From Function to Structure and Role in Cell Biology |
| Q55514831 | The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health. |
| Q90426204 | The Human Transient Receptor Potential Melastatin 2 Ion Channel Modulates ROS Through Nrf2 |
| Q52563269 | The Novel Roles of Connexin Channels and Tunneling Nanotubes in Cancer Pathogenesis. |
| Q90423341 | The Role of Metabolic Plasticity in Blood and Brain Stem Cell Pathophysiology |
Search more.